OR WAIT 15 SECS
Amicus Therapeutics has entered into a strategic gene therapy development and manufacturing collaboration with Brammer Bio, which is a part of Thermo Fisher Scientific.
Biotech company, Amicus Therapeutics, has entered into a strategic gene therapy development and manufacturing collaboration with Brammer Bio, which is a part of Thermo Fisher Scientific, it was announced in a July 1, 2019 press release.
Under the terms of the agreement, Thermo will provide Amicus with immediate clinical and commercial manufacturing capabilities and capacity for its intrathecal AAV Batten disease gene therapy programs. Additionally, Amicus stated that it has established a network for plasmid supply through multiple long-term supply agreements from plasmid suppliers that it will use to support the progression of all current gene therapy pipeline programs.
“As we advance one of the industry’s leading gene therapy pipelines, our partnership with Brammer Bio, now part of Thermo Fisher, is a significant next step in fulfilling our manufacturing strategy so that we can deliver novel gene therapies to more people living with rare genetic diseases as quickly as possible, especially in devastating diseases like Batten’s, where time is of the essence,” said John F. Crowley, chairman and chief executive officer of Amicus, in a press release.
“We are thrilled to begin working with Amicus and to contribute to the successful development of their gene therapy pipeline,” added Chris Murphy, vice-president and general manager, viral vector services at Thermo Fisher Scientific. “We see this as a strong strategic relationship to enable manufacturing of a deep gene therapy pipeline across various stages of development for people with devastating genetic diseases. These therapies have the potential to transform patients’ lives and, as an organization, we are delighted to support partners such as Amicus as they advance tomorrow's potential medicines.”
Source: Amicus Therapeutics